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Abstract: A nebulized formulation of formoterol, Perforomist®, 20 µg/2 ml, has been available 
since 2007 for the maintenance treatment of chronic obstructive pulmonary disease (COPD). 
We review the safety and efficacy data obtained during its development. In a dose-finding 
study, formoterol inhalation solution (FFIS) was similar to the formoterol originator, Foradil® 
12 µg DPI (FA) in patients with COPD. In a 12-week efficacy study, FFIS manifested a rapid 
onset of action and FEV1 peak, AUC0–12, and trough levels similar to FA. No loss of efficacy, 
tachyphylaxis, was observed over 12 weeks of regular administration. In placebo-controlled 
studies in COPD patients receiving maintenance tiotropium, the addition of FFIS significantly 
augmented  bronchodilation  over  the  6-week  treatment  duration,  signifying  that  nebulized 
formoterol can further improve lung function in patients who are receiving tiotropium without 
an observed increase in adverse reactions. The safety profile of FFIS during 12-week and 
1-year studies revealed adverse events that were similar to those of placebo and FA. Cardiac 
rhythm studies, including frequent ECGs and Holter monitoring, did not indicate any increase 
in rate or rhythm disturbances greater than placebo or FA. We conclude that maintenance use 
of Perforomist® is appropriate for patients with COPD who require or prefer a nebulizer for 
management of their disease.
Keywords: long-acting bronchodilator, β-agonist, chronic bronchitis, pulmonary emphysema, 
Perforomist®, chronic obstructive pulmonary disease
Readers of this journal will be well aware of the burden of chronic obstructive   pulmonary 
disease (COPD) on patients, society, and the health care system. In the absence of disease 
modifying medications, our main efforts are directed to smoking cessation, symptom 
relief, and improvements in the health status of patients. To this end, the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) has made recommendations concerning 
bronchodilator choices for each stage of disease   severity.1 In COPD from moderate 
through to more severe stages of the disease,   “regular treatment with long-acting 
bronchodilators is more effective and convenient than with short-acting agents”. In the 
United States, three long-acting bronchodilators are currently available and approved for 
the maintenance treatment of COPD; one is an anticholinergic agent (tiotropium) and 
two are beta-adrenergic agents (formoterol and salmeterol). Of these, formoterol has 
the unique properties of being a ‘full’ agonist and with an onset of action that is as rapid 
as any other beta-adrenergic agent including albuterol.2 It also provides a full 12-hour 
duration of action, with a potency of bronchodilation that equals or exceeds that of all 
other bronchodilators, and an excellent safety profile in COPD patients, particularly 
when used in the moderate dosages that are approved in the United States.3International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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To obtain the greatest utility from the available 
long-acting agents, they have to meet the needs of the 
diverse COPD population. Inhalation is the preferred route 
of administration; medication can be delivered in many 
ways (for example, dry powders [DPIs], pressurized metered 
dose inhalers [pMDIs]) but for a substantial proportion of 
the COPD population, nebulization is the preferred route.4,5 
This may be because the patient has difficulty using another 
method properly due, for example, to poor motor coordina-
tion, poor manual dexterity, arthritis involving the hands, 
neurological problems such as a stroke or Parkinson’s disease, 
or poor eyesight or mental capacity. For the mostly older 
COPD population, who typically has one or more of these 
  comorbidities, such limitations are not uncommon. There are 
also patients who have a personal preference for nebulizer 
treatment or feel it provides them with a better outcome 
than a DPI or MDI. Results of studies in which the efficacy 
of various delivery methods is compared, as reviewed by 
Dolovich and colleagues for a consortium of Pulmonary 
and Allergy Societies,5 have not shown an advantage for any 
other delivery method over nebulization. Among the long-
acting agents, formoterol is the only bronchodilator that is 
available in a nebulizer formulation. Two such formulations 
were approved in 2007, arformoterol, a single enantiomer of 
formoterol marketed as Brovana®, and racemic formoterol, 
marketed as Perforomist®. In the present report the properties 
of Perforomist®, the published information concerning its 
efficacy and safety, and recommendations for its use in the 
maintenance care of COPD are reviewed.
Seven studies were conducted as part of the clinical 
program for Perforomist® (Table 1) ranging from Phase II 
single-dose dose-ranging studies to Phase IV comparator and 
add-on studies in which a total of 1374 patients were enrolled. 
All studies were randomized, controlled multicenter studies 
conducted at sites throughout the United States.
Pharmacokinetics  
and pharmacodynamics
A single-dose 7-way crossover study was conducted to 
establish the dose of nebulized formoterol (FFIS) compa-
rable to the formoterol DPI product marketed in the United 
States (12 µg Foradil®, FA) by determining the broncho-
dilatory response in COPD patients to a single nebulized 
dose of FFIS at various doses (2.5, 5, 10, 20, and 40 µg), 
FA, or placebo.6 Treatment with FFIS 40 µg produced sig-
nificantly higher bronchodilation than FA when the primary 
efficacy variable, FEV1AUC0–12, was compared, and FFIS 
20 µg was the dose determined to be comparable to FA. 
Secondary efficacy endpoints, such as FEV1 by timepoint, 
peak FEV1, and trough FEV1 supported the comparability 
Table 1 Clinical studies of nebulized formoterol (FFIS) in COPD
Reference Objective Design* Treatments† # Pts
Gross et al 20086 Dose selection SD, DB, DD, XO 2.5 µg FFIS 47
5.0 µg FFIS 47
10 µg FFIS 47
20 µg FFIS 47
40 µg FFIS 47
Placebo  47
Gross et al 20086 Pharmacokinetics SD, OL, XO 10 µg FFIS 12
20 µg FFIS 12
244 µg FFIS 13
FA  12
Gross et al 2008a14 Efficacy and safety 12-wk, DB, DD, PG FFIS 123
Nelson et al 200725 FA 114
Placebo 114
Sutherland et al 20097 Active comparison 2-wk, OL, XO FFIS 109
IPR/ALB 109
Donohue et al 200826 Long-term safety 52-wk, OL, PG FFIS 463
FA 106
Tashkin et al 200835 Add-on tiotropium 6-wk, DB, PG, PC TIO + FFIS 67
Tashkin et al 200937 TIO + placebo 63
Hanania et al 200936 Add-on tiotropium 6-wk, DB, PG, PC TIO + FFIS 78
Tashkin et al 200937 TIO + placebo 77
†FFIS, formoterol fumarate inhalation spray for nebulization (20 µg unless otherwise specified); FA, formoterol fumarate DPI 12 µg; IPR/ALB, ipratropium bromide (18 µg)/
albuterol sulfate (103 µg) MDI; TIO, tiotropium bromide 18 µg.
Abbreviations: SD, single dose; DB,double blind; XO, crossover; PG, parallel group; DD, double dummy; PC, placebo controlled. International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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of FFIS 20 µg and FA. Mean FEV1AUC0–12 increased by 
2.3 L/hour after either FFIS or FA treatment compared 
with a slight decrease after   placebo. The percentage of 
patients that responded to treatment with $15% increase in 
  bronchodilation was   dose-dependent, with 72.3% respond-
ers after FFIS 20 µg compared with 85.1% after FA. Time 
to onset of bronchodilation was more rapid after FFIS 20 µg 
(3.9 minutes) than after FA (13.5   minutes). The duration of 
action of FFIS was comparable to that of FA, given that FEV1 
at 12 hours   post-dose (trough FEV1) was 9% above pre-dose 
levels in both groups. A crossover study of twice-daily FFIS 
versus four-times-daily ipratropium-albuterol combination 
  treatment (IPR-ALB) confirmed the 12-hour duration of 
bronchodilation, demonstrating that trough FEV1 improved 
from baseline to Day 14 with FFIS but not IPR-ALB.7
A pharmacokinetic study confirmed the comparability of 
FFIS 20 µg and FA by urine pharmacokinetics.6 Blood and 
urine samples for PK analysis were taken pre-dose after which 
nebulized FFIS (10 µg, 20 µg, or 244 µg) or FA 12 µg was 
administered. The mean amount of drug excreted unchanged 
in 24-hour urine by those receiving FFIS 20 µg and FA was 
349.6 ± 190.3 and 406.3 ± 116.5, respectively, compared 
with 109.7 ± 56.0 for FFIS 10 µg and 3317.5 ± 1733.0 for 
FFIS 244 µg. At the time of the study, plasma formoterol 
fumarate levels could only be reliably measured following 
treatment with FFIS 244 µg, as concentrations following the 
other treatments were below the lower level of quantification 
(2.5 pg/mL), a problem previously observed with the DPI 
product.8
There were no clinically significant changes in clinical 
laboratory measures, with the exception of dose-dependent 
decreases in mean serum potassium ranging from -0.23 
to -0.68 mEq/L over the 24 hour period following dosing 
with FFIS 20 µg, FFIS 244 µg, and FA and increases in mean 
serum glucose at 1 hour post-dose with all treatments. There 
were no clinically significant changes in ECG evaluations 
other than a few minor shifts from baseline in P-R intervals 
and no differences in responses to treatment. Mean heart rate 
rose in the first 6 hours after FFIS 244 µg dosing.6
As previously shown with other formoterol formulations, 
these results with nebulized formoterol demonstrated: 1) a rapid 
onset of bronchodilation,2,9 2) linear kinetics and dose propor-
tionality in both pulmonary and nonpulmonary measures,8,10–12 
and 3) a linear relationship between urinary formoterol 
excretion and changes in serum potassium, serum glucose, and 
heart rate.13 Taken together, these results provided the dose 
selection and dose tolerance data necessary for further clinical 
development of the nebulized product at the 20 µg dose.
Efficacy
The efficacy of nebulized formoterol was first established 
when FFIS 20 µg was compared to marketed formoterol 
DPI (Foradil® 12 µg, FA) and placebo for 12 weeks in 
a randomized, double-blind, double-dummy trial. The 
primary outcome, FEV1AUC0–12 at week 12, was sig-
nificantly improved by 185 mL with FFIS treatment com-
pared with   placebo (P , 0.0001).14 The improvements in 
bronchodilation were observed starting on Day 1 of treat-
ment and did not diminish over the 12 weeks of treatment 
(Figure 1). Other spirometry measures (peak FEV1, trough 
FEV1, FEV1 at each timepoint, FVC AUC0–12) were also 
significantly improved with FFIS treatment compared with 
placebo at each visit. Results for the FA treatment group 
were similar to those for FFIS for each primary and second-
ary efficacy endpoint.
The improvement in bronchodilation was similar to 
that observed in previous studies of maintenance treatment 
with formoterol DPI15–17 and others, summarized by 
Steiropoulos et al,3 and the improvement of 185 mL14 would 
be considered clinically relevant to the patient.18 No decline 
in bronchodilation effectiveness was observed over the 
12-week treatment period with FFIS. This result is in contrast 
to those reported for the other nebulized LABA product, 
arformoterol, and for salmeterol, in which some tolerance 
developed within 12 weeks at all doses tested,19,20 although 
meaningful   pulmonary function improvements were main-
tained throughout a one-year study of arformoterol.21
Health-related quality of life improvements as dem-
onstrated by total scores on the St George’s Respiratory 
Questionnaire (SGRQ) as well as symptoms and impacts 
scores were observed with FFIS treatment (Figure 2), 
whereas FA-treated participants only demonstrated improve-
ment in symptoms scores.14 These mean improvements in 
FFIS-treated participants were $4 units, the threshold for 
clinically significant changes.22 Treatment with FFIS or FA 
also led to a 42% reduction in rescue albuterol use beginning 
in the first assessment period (day 1-week 4) and lasting 
throughout the 12 weeks of treatment.
The effect of twice-daily FFIS nebulizer treatment 
on pulmonary function was also compared to that of the 
marketed four-times-daily metered dose inhaler com-
bination ipratropium/albuterol product (Combivent®, 
IPR-ALB) in an open-label crossover study. The primary 
efficacy outcome (mean morning pre-dose FEV1 or trough) 
was significantly higher in the FFIS group after 2 weeks 
of treatment.7 Using a newly developed questionnaire, 
participants reported greater satisfaction with treatment, International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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a greater perception that the medication reached the lungs, 
and more control of their COPD when using FFIS com-
pared with IPR-ALB. Subgroup analyses by age, gender, 
and severity demonstrated that FFIS was significantly more 
effective than IPR-ALB and resulted in greater satisfaction 
in participants who were older, male, or had more severe 
COPD. Patients with more severe disease also preferred 
FFIS to IPR-ALB treatment.
Safety
Results of recent meta-analyses and reviews have raised 
  concerns regarding cardiovascular and other adverse effects 
of LABA treatment of COPD and asthma.23,24 In the pivotal 
safety and efficacy study, the incidence of adverse events (AEs) 
was similar across treatment groups (51%–60%), with the 
number of respiratory events,   including COPD exacerbations, 
trending higher in the placebo group.14 The most frequently 
reported AEs were headache (FFIS: 5.7%, FA: 4.4%, PLA: 
7.0%), nausea (FFIS: 4.9%, FA: 3.5%, PLA: 2.6%), diarrhea 
(FFIS: 4.9%, FA: 1.8%, PLA: 3.5%), COPD exacerbation 
(FFIS: 4.1%, FA: 6.1%, PLA: 7.9%), dizziness (FFIS: 
2.4%, FA: 7.0%, PLA: 0.9%), and cough (FFIS: 1.6%, FA: 
4.4%, PLA: 4.4%). There were no deaths or drug-related 
serious AEs, and the discontinuations from AEs occurred 
in 3.3%, 3.5%, and 8.8% of participants in the FFIS, FA, 
and placebo groups, respectively. Three participants (one 
in each group) discontinued after AEs of possible cardiac 
significance.25
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Figure 1 Time course of mean Fev1 response after first dose (Day 1) and 12 weeks of treatment in the ITT population.
Notes: FFIS: formoterol fumarate inhalation solution 20 µg BID and FA: formoterol fumarate DPI 12 µg BID. Data expressed as LS means adjusted for baseline Fev1. LS mean 
difference at each timepoint on Day 1 and week 12: P # 0.0007 and FA versus placebo P , 0.05.
Reprinted from Respiratory Medicine Volume 102, Gross NJ, Nelson HS, Lapidus RJ, et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD 
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Long-term safety was assessed in 569 participants in 
a 52-week active-control, open-label safety study.26 Most 
participants treated with FFIS (86%) completed at least 
6 months of treatment compared with 88% treated with 
FA. Comparable numbers of FFIS and FA participants 
  experienced at least one AE (Table 2), most of which were 
mild or moderate. Similar rates of death (1.3% FFIS, 1.9% 
FA), discontinuation due to AEs (39% FFIS, 36% FA), and 
serious AEs (16% FFIS, 18% FA) were observed.
In the long-term study, laboratory evaluations demonstrated 
little change in mean values from baseline to Week 10 or 
Week 52 for any parameter. More than 5% of participants 
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Figure 2 Change from baseline in SGRQ scores (LS means) after 12 weeks of treatment (or early termination). FFIS: formoterol fumarate inhalation solution 20 µg BID and 
FA: formoterol fumarate DPI 12 µg BID. *P # 0.03 versus placebo, (---): clinically meaningful change. 
Reprinted from Respiratory Medicine Volume 102, Gross NJ, Nelson HS, Lapidus RJ, et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD 
patients, pp. 189–197, Copyright © 2008, with permission from elsevier.
Table 2 Treatment emergent adverse events (TeAe) reported in $3% of participants in either group
Formoterol fumarate 
inhalation solution 20 μg BID 
(n = 463)
Formoterol fumarate dry 
powder inhalation 12 μg BID 
(n = 106)
Number (%) with $1 TeAe 340 (73.4) 83 (78.3)
COPD exacerbation 73 (15.8) 19 (17.9)
Upper respiratory tract infection 47 (10.2) 13 (12.3)
Nasopharyngitis 36 (7.8) 7 (6.6)
Bronchitis 32 (6.9) 10 (9.4)
Sinusitis 27 (5.8) 4 (3.8)
Acute bronchitis 22 (4.8) 3 (2.8)
Urinary tract infection 21 (4.5) 6 (5.7)
Headache 20 (4.3) 5 (4.7)
Cough 19 (4.1) 4 (3.8)
Pneumonia 18 (3.9) 2 (1.9)
Arthralgia 15 (3.2) 5 (4.7)
Diarrhea 16 (3.5) 2 (1.9)
Hypertension 14 (3.0) 3 (2.8)
Back pain 13 (2.8) 7 (6.6)
Insomnia 11 (2.4) 5 (4.7)
Dyspnea 7 (1.5) 5 (4.7)
Dizziness 6 (1.3) 4 (3.8)
Tooth abscess 1 (0.2) 4 (3.8)
From Donohue JF, Hanania NA, Fogarty C, et al. Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Resp Dis 2008;2: 
199–208. Copyright © 2008 by Sage Publications. 
Reprinted with permission from Sage.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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  experienced changes from normal to high in serum creati-
nine, uric acid, glucose, sodium, white blood cell count, and 
neutrophils, a result similar between treatment groups. In 
the FFIS group, mean changes from baseline to Week 52 for 
serum glucose and potassium were 0.4 mg/dL and 0.0 mEq/L, 
respectively. The incidence of clinically significant changes in 
laboratory values was low in each group.
Cardiac effects of FFIS treatment were monitored 
  carefully in the 12-week pivotal study.25 Although patients 
were excluded from the trial if they had an unstable 
cardiac condition, recent myocardial infarction, or QTc 
interval .0.46 ms, approximately 50% of enrolled patients 
  demonstrated cardiac abnormalities on screening ECGs, 
which was similar across treatment groups. The underlying 
comorbidities associated with COPD, including increased 
incidence of cardiovascular disease,27–29 are confounding 
factors in any analysis of COPD treatment. As many as half 
of COPD patients may have undiagnosed atrial tachycardia29 
and one-fifth may have heart failure.28 Neither FFIS nor 
FA treatment had clinically meaningful effects on mean 
or maximum heart rate (HR) or incidence of ventricular 
premature beats found with 24-hour Holter monitoring.25 
The incidence of arrhythmic events was also similar across 
groups and did not increase significantly throughout the 
study. ECG measurements demonstrated that mean changes 
from baseline in HR, PR interval, QRS complex, QT inter-
val, and R-R interval were comparable among the treatment 
groups at each time point. The proportions of participants 
who had a mean maximum change in QTc $60 ms at any 
time during the study were also comparable among groups 
(Table 3). Cardiovascular safety was also monitored in 
the 52-week study with ECGs at baseline, Week 10, and 
Week 52 (or early termination). Effects were small and 
comparable between treatment groups.
The results of the FFIS studies confirmed those of other 
large studies using an equivalent dose of formoterol DPI 
(12 µg)17,30–32 and demonstrated no adverse cardiovascular 
effects of nebulized formoterol treatment for 12 or 52 weeks 
in COPD participants. Unlike the previous meta-analysis,23 
there was no correlation between a decrease in potassium 
levels and duration of formoterol treatment in these   studies. 
Glucose levels, which rise in a dose-dependent manner 
with β2-agonist treatment,12 were unaffected by formoterol 
treatment. There were also no increases in mortality, serious 
adverse events, or COPD exacerbations with FFIS treatment 
in these studies. A recent large case-controlled study33 and a 
systematic review34 demonstrated the lack of increased risks 
of COPD exacerbations, cardiovascular deaths, respiratory 
deaths, or all-cause mortality with LABA treatment for 
COPD and, in fact, demonstrated the reduced risk of all-cause 
mortality33 and COPD exacerbations.34 A post-marketing 
surveillance study of formoterol DPI prescribed for 5,777 
patients with respiratory disease in the United Kingdom, 65% 
of whom had .12 months treatment, also demonstrated the 
tolerability of formoterol.32
Add-on studies with tiotropium
The efficacy and safety of adding twice-daily nebulized for-
moterol treatment to once-daily maintenance treatment with 
tiotropium (Spiriva®, TIO) were evaluated in moderate-to-
severe COPD participants randomized to receive FFIS 20 µg 
or nebulized placebo while maintaining treatment with TIO 
for 6 weeks in two studies. Bronchodilation, as defined by 
the primary efficacy endpoint FEV1AUC0–3 at week 6, was 
significantly improved with the addition of FFIS to mainte-
nance TIO by 185–190 mL over placebo.35–37 FEV1 measured 
pre- and post-dose over 3 hours on day 1 and week 6 is 
shown in Figure 3, illustrating the significant improvements 
in FEV1 after treatment with FFIS at the beginning and end 
of the study period. A gain of 410 mL with FFIS added to 
TIO compared with 280 mL with the addition of placebo to 
TIO was observed in the second study.36 Pre-dose inspiratory 
capacity (IC) did not significantly differ between treatment 
groups in either study; however, post-dose IC, measured only 
in the second study,36 was significantly improved by FFIS/
TIO treatment versus PLA/TIO both on day 1 and week 6 
(Figure 4).
Table 3 Maximum change from baseline in QTcB and QTcF 
during 12 weeks’ treatment with formoterol fumarate inhalation 
solution 20 µg BID (FFIS group), formoterol fumarate dry powder 
inhaler 12 µg BID (FA group), or placebo in patients with chronic 
obstructive pulmonary disease
Category FFIS  FA  Placebo 
(n = 122) (n = 112) (n = 111)
QTcB
 , 30 ms 100 (82.0) 91 (81.3) 93 (83.8)
  30,60 ms 22 (18.0) 19 (17.0) 16 (14.4)
 $ 60 ms 0 2 (1.8) 2 (1.8)
QTcF
 , 30 ms 109 (89.3) 95 (84.8) 99 (89.2)
  30,60 ms 11 (9.0) 16 (14.3) 11 (9.9)
 $ 60 ms 2 (1.6) 1 (0.9) 1 (0.9)
Notes: values are no. (%) of patients. QTcB = QT interval corrected for heart 
rate (Bazett’s correction), QTcF = QT interval corrected for heart rate (Fridericia’s 
correction). 
Reprinted with permission of the publisher from: Nelson HS, Gross NJ, Levine B, 
et al. Cardiac safety profile of nebulized formoterol in adults with COPD. Clinical 
Therapeutics. 2007;29:2167–2178. Copyright © 2007 by excerpta Medica, Inc.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Baseline dyspnea was similar between groups in both 
studies. After 6 weeks of treatment, however, there was a 
difference in TDI scores between groups favoring FFIS/TIO, 
with a mean difference from placebo of 1.80 in the first study 
(P = 0.0002)35 and 0.72 in the second study (P = 0.11).36 More 
participants receiving FFIS/TIO experienced a clinically 
meaningful improvement ($1)38 in dyspnea (57.7% versus 
31.1% with PLA/TIO, Figure 5);35 similar responder rates 
were observed in the second study (58.4% versus 47.2% with 
PLA/TIO).36 Several respiratory symptoms (total, shortness 
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of breath, chest tightness, nighttime awakenings) were sig-
nificantly improved with FFIS/TIO use compared with PLA/
TIO in one study,35 but only shortness of breath demonstrated 
a difference at two timepoints during the other study.36 Rescue 
albuterol use was significantly reduced with FFIS/TIO over 
PLA/TIO treatment in both studies.
Health-related quality of life (SGRQ) scores did not differ 
between groups after TIO run-in or after the treatment period 
in either study, with the exception of an improved change 
in symptoms score in the FFIS/TIO group in one study.35 
Also, the number of participants experiencing a clinically 
meaningful improvement in SGRQ (.4)22 was greater in the 
FFIS/TIO group in the total score and individual components 
in both studies.
These results are not surprising, as they have also 
been reported previously with maintenance treatment with 
formoterol DPI plus tiotropium39–43 and were recently 
well summarized.44 However, the degree of the benefit in 
lung function by using two bronchodilators with distinct 
mechanisms of action was dramatic and occurred after a 
lengthy run-in period with tiotropium designed to stabilize 
its effect on pulmonary function. The rapid onset of bron-
chodilation with formoterol administration compared with 
tiotropium may contribute to its additive benefit.45 Treatment 
with both formoterol and tiotropium has been demonstrated 
to provide greater improvement in lung function than the 
LABA/ICS combination of salmeterol and fluticasone.46 The 
improvement in post-dose inspiratory capacity and dyspnea 
may be linked due to the beneficial effects of LABAs on 
small airway patency, improving the hallmark pulmonary 
hyperinflation of COPD.47 The observed benefits in these 
nebulized formoterol studies support recent recommenda-
tions to combine therapies when needed to treat COPD.1,48
Adverse events are summarized with greater power 
by combining results from the two almost identical trials 
with FFIS/TIO.37 More participants treated with PLA/TIO 
experienced adverse events (45.7% compared with 31.0% 
for FFIS/TIO), including a greater number of COPD exac-
erbations. More PLA/TIO participants withdrew due to AEs 
and had serious AEs (cellulitis, pneumonia, COPD exacer-
bation, angina) than those treated with FFIS/TIO. Clinical 
laboratory evaluations were generally within normal range International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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at screening and week 6. One participant treated with FFIS/
TIO experienced a clinically significant decrease in serum 
potassium to 3.1 mmol/L. ECG changes were minimal 
throughout the studies, with change in mean heart rate being 
greater for PLA/TIO in one study (1.5 bpm versus 0.2 bpm 
for FFIS/TIO)35 and for FFIS/TIO in the other (1.3 bpm 
versus 0.8 bpm for PLA/TIO).36 Changes in QTcB $ 60 ms 
were observed in 3 FFIS/TIO and 3 PLA/TIO participants 
in the two studies.
Previous large placebo-controlled trials demonstrated 
that tiotropium added to baseline COPD medications 
including inhaled corticosteroids and LABAs reduced COPD 
exacerbations.49,50 These FFIS + TIO study results suggest that 
there may be a safety benefit of adding nebulized formoterol 
to tiotropium, supporting a recent 6-month study of formoterol 
DPI plus tiotropium that found a reduction in COPD exacerba-
tions compared with tiotropium alone.40 The results of these 
studies do not support previous suggestions that LABA treat-
ment for COPD may result in adverse safety consequences, 
including adverse cardiovascular effects, increased mortality, 
and increased respiratory mortality,23,24 although a treatment 
arm using nebulized formoterol alone was not included, 
making it more difficult to assess the safety benefit in these 
studies. Clearly, further studies, including long-term studies 
using the combination of drugs, will be required to explore the 
possible safety benefit for COPD patients of adding nebulized 
formoterol treatment to maintenance tiotropium.
Summary
In conclusion, a nebulized formulation of formoterol 
(Perforomist®) 20 µg/2 mL results in lung function changes 
that closely resemble those of the approved formoterol dry 
powder formulation (Foradil®) 12 µg, specifically the rapid 
onset of action and significant bronchodilation through-
out the subsequent 12 hours, without any loss of efficacy, 
subsensitivity, or tachyphylaxis, during 12 weeks of regular 
twice daily administration. The safety and adverse event pro-
files were not different from that of placebo or Foradil® dry 
powder. Cardiac outcomes in particular revealed no concern 
of increased rhythm disturbances. The nebulized formulation 
was well accepted by patients with COPD, being preferred to 
the dry powder agent by many. Even in COPD patients who 
had been stabilized on maintenance once daily tiotropium, 
the addition of nebulized formoterol resulted in significant 
further improvement in lung function. Perforomist® is safe 
and effective for maintenance treatment of COPD in patients 
who require a nebulized formulation of a long-acting beta-
agonist.
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